Sutasinee BoonsoponArmin MaghsoudlouNinani E. KomboC. Stephen FosterMassachusetts Eye Research and Surgery InstitutionOcular Immunology and Uveitis FoundationMahidol UniversityYale University School of MedicineHarvard Medical School2018-11-232018-11-232015-09-02European Journal of Ophthalmology. Vol.26, No.1 (2015), 30-35112067212-s2.0-84954054585https://repository.li.mahidol.ac.th/handle/20.500.14594/36336© 2015 The Authors. Purpose: To evaluate the effectiveness of a therapeutic trial of valganciclovir in patients with uveitis with positive Epstein-Barr virus early antigen D immunoglobulin G titers (EBV EA-D). Methods: We performed a retrospective chart review of 14 patients at the Massachusetts Eye Research and Surgery Institution who had uveitis with positive EBV EA-D but negative studies for all other causes of uveitis and were treated with valganciclovir 450 mg twice a day or valganciclovir 900 mg twice a day between January 2010 and August 2014. Results: Nine of 14 patients, who had presumed EBV reactivation with associated intraocular inflammation, were successfully treated with valganciclovir: 3 of these were treated with valganciclovir 450 mg twice a day and 6 were treated with valganciclovir 900 mg twice a day. Five of 14 patients failed to respond to valganciclovir with persistent inflammation after at least 2 weeks of valganciclovir therapy, and were subsequently treated with immunomodulatory therapy to control inflammation. Conclusions: Uveitis can be caused by EBV infection/reactivation. A therapeutic trial with valganciclovir 450 mg twice a day for 1 month in patients with uveitis with positive EBV EA antibody may be beneficial.Mahidol UniversityMedicineArticleSCOPUS10.5301/ejo.5000673